Table 1.
Autoantibody data at baseline
| Autoantibody positivity at IP1, n = 63 n (% of n = 63)a | |
|---|---|
| Individual autoantibodies at IP1 | 63/170 (37) |
| SMA | 30 (48) |
| ANA | 19 (30) |
| PCA | 7 (11) |
| ACyA | 7 (11) |
| xANCA | 3 (5) |
| Anti-TG/anti-TPO | 3 (5) |
| pANCA | 2 (3) |
| AMA | 1 (2) |
| AMiA | 1 (2) |
| Anti-LKM | 0 (0) |
| Patients with multiple autoantibodies at IP1 | 10 (16) |
| SMA + ACyA | 2 (3) |
| SMA + ANA | 2 (3) |
| SMA + PCA | 1 (2) |
| SMA + xANCA | 1 (2) |
| ANA + anti-TG/anti-TPO | 1 (2) |
| PCA + anti-PR3 | 1 (2) |
| AMA + ACyA | 1 (2) |
| ANA + SMA + PCA | 1 (2) |
ACyA, anti-cytoplasmatic antibodies; AMA, anti-mitochondrial antibodies; AMiA, anti-mitotic antibodies; ANA, anti-nuclear antibodies; IP1, baseline time during induction phase; LKM, liver kidney microsome; pANCA, perinuclear anti-neutrophil cytoplasmatic antibodies; PCA, parietal cell antibodies; PR3, proteinase-3; SMA, smooth muscle antibodies; TG, thyroglobulin; TPO, thyroid peroxidase; xANCA, atypical anti-neutrophil cytoplasmatic antibodies.
a
Unless otherwise stated.